clinical trial

Home/Tag: clinical trial

Good News from Trio of Phase One Zika Vaccine Trials

In early results published in the Lancet, researchers report that an investigational Zika vaccine was well-tolerated and stimulated potentially protective immune responses in three phase 1 clinical trials, one of which was conducted at Saint Louis University. More than 90 percent of study volunteers in the three trials who received the investigational vaccine demonstrated an immune

December 7th, 2017|Categories: Around The State, Clinical Trials|Tags: , , |

Early Cleveland Clinic trial of stem cells for multiple sclerosis shows promise, by Brie Zeltner ~ September 12, 2014 CLEVELAND, Ohio — An early clinical trial testing the use of a patient's own stem cells to treat, or even reverse, multiple sclerosis has shown some positive results, Cleveland Clinic researchers reported this week. The Phase 1 trial, unique in the United States, tested the safety and

Clinical trial using iPS cells litmus test for promoting regenerative medicine

The Japan Times, by The Yomiuri Shimbun ~ September 16, 2014 The latest clinical trial is the first step of epoch-making research that could evolve into regenerative medicine. After careful safety assessment, putting the latest result into practical use should be promoted. A team led by RIKEN ophthalmologist Masayo Takahashi transplanted retina cells produced from

New Clinical Trial for Children with Autism to Target Parents

Saint Louis University, by Riya V. Anandwala SLU Researchers will help parents apply strategies that could improve their child’s behavioral problems ST. LOUIS - In a first of its kind clinical trial, Debra Zand, Ph.D., and her team at Saint Louis University, will run an intervention program to help parents address and manage their children's

StemCells, Inc. to Discuss Plans for Advancing Clinical Studies in Spinal Cord Injury and Age Related Macular Regeneration

Globe Newswire, source: Stem Cells, Inc. ~ January 7, 2014 NEWARK, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary

Heart Disease Therapy Cleared for Phase 2 Clinical Trial to be Funded by Stem Cell Agency

California Institute for Regenerative Medicine, by Kevin McCormack ~ December 23, 2013 San Francisco, CA – A stem cell therapy aimed at treating patients who have had a heart attack has been given approval to begin a Phase 2 clinical trial funded by California’s stem cell agency, the California Institute for Regenerative Medicine (CIRM). The

Trials at Washington U. medical school offer hope for Alzheimer’s treatment

St. Louis Post-Dispatch, by Michelle Munz ~ October 3, 2013 Brent Whitney, 34, found out two years ago he has the same inherited gene mutation that caused early onset Alzheimer’s disease and took the lives of his father, grandmother and 10 of his grandmother’s 13 siblings. His voice cracks as the married father of two

Novel Therapeutic Cancer Vaccine Goes to Human Clinical Trials, by Staff ~ October 7, 2013 “It is rare to get a new technology tested in the laboratory and moved into human clinical trials so quickly,” said Dr. Glenn Dranoff. “We’re beyond thrilled with the momentum, and excited about its potential.” A cross-disciplinary team of scientists, engineers, and clinicians announced today that they have

October 7th, 2013|Categories: Cancer, Disease Specific|Tags: , , |

Better diagnostic, prognostic tests are one step toward better ALS treatment to this startup

MedCity News, by Deanna Pogorelc ~ October 1, 2013 It might not seem like a fitting name for a medical company – or at least one that you’d expect – but Iron Horse Diagnostics actually makes a lot of sense. The name comes from baseball great Lou Gehrig, nicknamed “The Iron Horse.” He died from

StemCells gets FDA nod for spinal cord injury trial

San Francisco Business Times, by Ron Leuty ~ October 2, 2013 Where Geron Corp. failed, StemCells Inc. hopes to thrive. The Food and Drug Administration signed off on an expansion of a Phase I/II clinical trial to the United States, allowing the Newark company (NASDAQ: STEM) to enroll patients in a trial that injects its